Abstract
Nature Reviews Immunology 11, 658–671 (2011) In the original version of this article, in the section under the subheading “CNS-specific NK cells in disease” on page 668, the humanized antibody daclizumab was incorrectly described as being specific for the IL-2 receptor β-chain (CD122). The correctedsentence now reads: “These findings might be relevant to the mode of action of daclizumab, a humanized antibody specific for the IL-2 receptor α-chain (CD25)”.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
